V503

Pipeline

Status by Indication[3][1]

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Papilloma7 trials

Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)

Completed·Merck & Co.·Phase 3·NCT03903562·1,990 enrolled

A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)

Completed·Merck & Co.·Phase 3·NCT00943722·3,074 enrolled

Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)

Active, not recruiting·Merck & Co.··NCT02653118·4,453 enrolled

Show 4 more trials

A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).

Completed·Merck & Co.·Phase 3·NCT01254643·100 enrolled

A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)

Completed·Merck & Co.·Phase 3·NCT01047345·924 enrolled

A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)

Completed·Merck & Co.·Phase 3·NCT01984697·1,518 enrolled

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

Completed·Merck & Co.·Phase 3·NCT03158220·1,212 enrolled

Immunogenicity2 trials

Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)

Completed·Merck & Co.·Phase 3·NCT01304498·600 enrolled

Efficacy, Immunogenicity, and Safety Study of the 9vHPV Vaccine in Japanese Males (V503-064)

Completed·Merck & Co.·Phase 3·NCT04635423·1,059 enrolled

Papillomavirus Infections2 trials

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Immunogenicity and Safety of V503 in Chinese Females Aged 10 to 45 Years Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine

Not yet recruiting·Merck & Co.·Phase 3·NCT07785843·930 enrolled

A Phase 3 Randomized, Double-Blinded, Controlled With GARDASIL® Efficacy, Immunogenicity and Safety Study of V503 [a 9-Valent HPV Vaccine] in Chinese Women 20 to 45 Years of Age

Active, not recruiting·Merck & Co.·Phase 3·NCT03998254·6,000 enrolled

Immune Response1 trial

A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)

Completed·Merck & Co.·Phase 3·NCT02114385·500 enrolled

NAC1 trial

A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)

Completed·Merck & Co.·Phase 3·NCT00988884·1,241 enrolled

1 more indication

Vaccine1 trial

A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007)

Completed·Merck & Co.·Phase 3·NCT01073293·1,054 enrolled

Details

Drug Info

Related News